Kelyniam Global IncOTC Pink - Current Information:KLYG
- LAST PRICE0.0419
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 0.0419
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Time | Volume | KLYG |
|---|
Apr 2, 2024
NEOS Cranial LOOP(TM) Receives FDA Clearance for CustomizedBone(TM) Use, from 12:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
12:00AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kelyniam Global Inc | 1.3M | -1.7x | --- |
Brain Scientific Inc | 932.0K | -0.1x | --- |
NewCardio Inc | 30.0 | 0.0x | --- |
Motus GI Holdings Inc | 416.9K | 0.0x | --- |
InVivo Therapeutics Holdings Corp | 1.1M | -0.1x | --- |
Wellness Center USA Inc | 52.0K | 0.0x | --- |
Company Information
Kelyniam Global, Inc. is a custom design-to-build medical device manufacturing company. The Company specializes in the delivery of cranial implant technologies to neurologically dependent patients. The Company is engaged in the production of custom prosthetics utilizing computer-aided design and computer-aided manufacturing of medical-grade polymers. Its Engineering Division uses Bio-Computer Aided Design (CAD) Computer Aided Manufacturing (CAM) technology to provide replicated cranial implants to replace damaged bone structures. Its product, PEEK-Optima, is engineered for biocompatibility. Derived from the patient’s computed tomography (CT) data, the Company’s 3D BIO-CAD/CAM software is used to transfer the details found on the edge of the defect directly to the implant edge. Its K-Plans include ke24, ke72 and kp5day. The Company’s emergency plan, ke24, provides precision-replicated, patient-specific cranial implants in approximately 24 hours.
Contact Information
- Headquarters
- 97 River RdCOLLINSVILLE, CT, United States 06019-3246
- Phone
- 800-280-8192
- Fax
- 501-641-2000
Executives
- Chairman of the Board, Chief Executive Officer
- Ross Bjella
- Chief Financial Officer
- Terrance Kurtenbach
- Chief Operating Officer
- Christopher Breault
- Vice President - Sales and Marketing
- Mark Chenoweth
- Vice President - Sales and Business Development
- Mark Smith
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3M |
|---|---|
Revenue (TTM) | $517.7K |
Shares Outstanding | 29.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.42 |
EPS | $-0.03 |
Book Value | $0.00 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 2.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -93.80% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
